HOUSTON - Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotech firm focused on developing cancer and obesity treatments currently valued at $2.76 million, has announced the expansion of its intellectual property portfolio with new patents issued in the United States and New Zealand. According to InvestingPro data, the company's stock has seen significant volatility, trading at $0.63, near its 52-week low of $0.59. The U.S. Patent and Trademark Office granted a Notice of Allowance for a patent titled "P-ethoxy nucleic acids for STAT3 inhibition," and the New Zealand Intellectual Property Office awarded Patent No. 741793 for a liposomal formulation.
The new U.S. patent enhances protection for Bio-Path's STAT3 program, which is set to progress into non-small cell lung cancer treatment. While CEO Peter Nielsen expressed the company's pride in its growing IP portfolio, InvestingPro analysis reveals the company faces financial challenges with weak profit margins and a negative EBITDA of -$12.35 million in the last twelve months. InvestingPro subscribers have access to 13 additional key insights about BPTH's financial health and market position. Nielsen also highlighted the company's commitment to advancing clinical programs to deliver new medicines for patients with obesity and cancer.
Bio-Path's strategy includes actively filing patent applications relevant to its technology and business approach. The company's patent holdings now consist of seven U.S. patents and 61 foreign patents, covering 26 countries. Additionally, there are three pending patent applications in the U.S. and five allowed applications in foreign jurisdictions.
The company's DNAbilize® platform has produced a pipeline of RNAi nanoparticle drugs administered through intravenous infusion. Its lead product candidate, prexigebersen, is undergoing a Phase 2 study for blood cancers, while a modification, BP1001-A, is in a Phase 1/1b study for solid tumors. BP1002, targeting the Bcl-2 protein, is under evaluation for treating blood cancers and solid tumors, such as acute myeloid leukemia. Furthermore, an Investigational New Drug (IND) application is expected for BP1003, a liposome-incorporated STAT3 antisense oligodeoxynucleotide developed as a STAT3 inhibitor.
This report is based on a press release statement from Bio-Path Holdings. The company's forward-looking statements are subject to uncertainties, including the ability to raise additional capital, the success of clinical development, and maintaining IP rights. Investors should note that Bio-Path's next earnings report is scheduled for March 7, 2025. For comprehensive analysis and detailed financial metrics, access the full Pro Research Report available on InvestingPro, which provides in-depth coverage of BPTH along with 1,400+ other US stocks.
In other recent news, Bio-Path Holdings, Inc. has been making significant strides in its clinical trials for cancer treatments. The company's Phase 1/1b trial of BP1001-A for solid tumors and Phase 2 study of prexigebersen for Acute Myeloid Leukemia (AML) have yielded promising results. Bio-Path is also progressing with a Phase 2 trial in AML and developing treatments for obesity in Type 2 Diabetes patients. The firm has also announced promising results from its preclinical studies, suggesting that BP1001-A could be a potential treatment for obesity and related metabolic disorders in Type 2 diabetes patients.
Bio-Path has also faced challenges with potential delisting from the Nasdaq over its share price and has had to discontinue Phase 1 trials for BP1002 due to difficulties in patient enrollment. These are recent developments and part of the ongoing journey of Bio-Path in the biotech industry. As for future expectations, analysts from various firms have projected further advancements in the company's clinical programs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.